Member Info for havegun

Am hoping this year SB and co deliver the goods,we sure have waited long enough.

I take it you are not a shareholder handofjohnson. The

Review will have been concluded now.So I would expect RNS January with final results.

Need to knowf this is dead or alive.If dead ok if not then we need to know the latest now.

Sorry to hear you say you have sold up.I think the opposite and when the final results come through I reckon they will be good and a surge in price I expect.If I were you and are now out of this I would not bother looking again at it because it may upset you.

merry Christmas to all shareholders and lets us have a very prosperous new year.

to add at this crazy price.

Are only at the beginning,This company with more deals is going up and up.

https://youtu.be/29w1FYiHL8Y

man was right then.Were are the trolls apologies.

falling into place.

will go crazy when we get some good news

BOTAK, been following this for quite a while.i bought flying brands some time ago and that is proving good.Now this looks to be in the same Mould.

Bought in looks good.

CIC Capital Ltd Convertible Unsecured Loan Stock RNS Number : 6667Y CIC Capital Ltd 07 December 2017 CIC CAPITAL FUND LTD Convertible Unsecured Loan Stock ISSUE OF €20.00 MILLION NOMINAL OF 6.5 PER CENT. CONVERTIBLE UNSECURED LOAN STOCK 2022 AT €500 PER €500 NOMINAL UNIT CIC Capital Fund Limited ("CIC Fund") a Canadian public Close Ended Fund issuer is pleased to advise the following: Convertible Unsecured Loan Stock ('CULS") The CULS is made available under the Placing at a placing price of €500 per CUL nominal. The interest rate on the CULS will be 6.5 per cent. per annum, payable quarterly in arrears. CULS Holders will be able to convert their CULS into B Class Special Series non-voting on a quarterly basis throughout the life of the CULS, commencing on 31 December 2017 and all outstanding CULS will be repayable at par on 31 December 2022. The Conversion Price is €1.15. CIC Fund confirms that regulated intermediaries receive 12% commission on the placement of CULS to sophisticated investors. Directors of the Company have purchased 1,400 CULS. The Board believes that introducing structural gearing should enable the Company to generate increased total returns over the longer term by taking immediate action to fund opportunities that come available. CIC Fund normal client funds have a specific purpose use caveat for release. The Directors intend to apply the net proceeds of the Placing, which will be approximately €17.60 million, for general corporate purposes in line with the Company's business strategy. Public Listing Convertible Unsecured Loan Stock ('CULS") The CULS will be fully tradable on a designated European Stock Exchange to be effected on or before 31 January 2017. A separate announcement is to be made in the very near future detailing the trading platform in Europe and information circular. Voting Conversion Share Value Max No. of Securities Capital Fund € € COMMON STOCK yes to B class 0.06 - B CLASS no to common 1.20 180 million 216,000,000 CULS no to B class

CIC Capital Ltd Shareholder Notice RNS Number : 5234Y CIC Capital Ltd 06 December 2017 CIC CAPITAL FUND LTD Shareholder Notice CIC Capital Fund Limited ("CIC Fund") is pleased to advise the following: Public Listing of B Class Shares A listing of Special Series B Class Shares Non Voting ("B Class Shares") on the Luxembourg Stock Exchange with a duel listing on the London Stock Exchange Specialist Fund Segment. The B Class Share public fund has been established to raise capital by the issue of 180 Million non-voting B Class Shares at EURO �1.20 per share. CIC Fund will direct the proceeds to providing Convertible Loans to highly prospective companies that will be publicly tradable as detailed in press release detailed 11 June 2017. Share holders may convert their current common shares to B Class shares with a 20% discount of expected listing price and should contact CIC Fund on a urgent basis to obtain further information. Shareholders in the conversion to B Class Shares will have the option to at any time convert back to common shares and have adjustment clauses on any fluctuations in share trading price to ensure conversion risks are removed and to maximize shareholder returns Stuart J. Bromley, a Director of CIC Fund has elected to convert 60 million common shares to 3.6 million B Class shares and voluntarily negated the 20% discount (no self dealing) in favor of common shareholder interests. CIC Fund will announce on Thursday December 7, 2017 a public listing of its convertible unsecured loan stock ("CULS") in January 2017, which will also allow common shareholder participation and the ability to also trade their shares. ENQUIRIES CIC Capital Fund Limited: Bromley@CICapitalFund.com This information is provided by RNS The company news service from the London Stock Exchange END NRAFSFSIMFWSEFE QUICK LINKS Equity Home Equity Prices and Performance Latest announcements OUR PRODUCT PORTFOLIO www.trustnet.com www.trustnetoffshore.com www.trustnetmiddleeast.com

Share Tweet Print RSS Nuformix PLC (NFX) Nuformix PLC Appointment of Broker RNS Number : 1048Y Nuformix PLC 01 December 2017 Nuformix plc ("Nuformix" or "the Company") Appointment of Broker Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce the appointment of Beaufort Securities Limited as the Company's broker. Follow Nuformix on Vox Markets: follow at www.**********.co.uk/company/NFX and www.nuformix.com ENDS Enquiries: Nuformix plc Dan Gooding, Chief Executive Officer +44 (0)1223 423667 Beaufort Securities Limited (Joint Broker) Jon Belliss +44 (0)20 7382 8300 Gable Communications Ltd John Bick / Justine James +44 (0)20 7193 7463 About Nuformix plc www.nuformix.com Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules. Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002. Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L. This information is provided by RNS The company news service from the London Stock Exchange END APPFSWSWFFWSEEE QUICK LINKS Equity Home Equity Prices and Performance Latest announcements OUR PRODUCT PORTFOLIO www.trustnet.com www.trustnetoffshore.com www.trustnetmiddleeast.com www.i

wonder how much this is going to tank today

No nothing was mentioned about the free shares.I personally as I have said before willl not be selling because I believe there will be even more free shares in the future as the company gets paid in shares of the companies they advise.

lost thousands when this was FORTE ENERGY and I would never buy this load of crap.